

# TRIALPANORAMA: Database and Benchmark for Systematic Review and Design of Clinical Trials

Zifeng Wang<sup>1</sup> Qiao Jin<sup>2</sup> Jiacheng Lin<sup>1</sup> Junyi Gao<sup>3,4</sup> Jathurshan Pradeepkumar<sup>1</sup>  
 Pengcheng Jiang<sup>1</sup> Benjamin Danek<sup>1</sup> Zhiyong Lu<sup>2</sup> Jimeng Sun<sup>1</sup>

<sup>1</sup>University of Illinois Urbana-Champaign

<sup>2</sup>National Institutes of Health

<sup>3</sup>University of Edinburgh

<sup>4</sup>Health Data Research UK

Correspondence: {zifengw2, jimeng}@illinois.edu

<http://ryanwangzf.github.io/projects/trialpanorama>

## Abstract

Developing artificial intelligence (AI) for vertical domains requires a solid data foundation for both training and evaluation. In this work, we introduce TRIALPANORAMA, a large-scale, structured database comprising 1,657,476 clinical trial records aggregated from 15 global sources. The database captures key aspects of trial design and execution, including trial setups, interventions, conditions, biomarkers, and outcomes, and links them to standard biomedical ontologies such as DrugBank and MedDRA. This structured and ontology-grounded design enables TRIALPANORAMA to serve as a unified, extensible resource for a wide range of clinical trial tasks, including trial planning, design, and summarization. To demonstrate its utility, we derive a suite of benchmark tasks directly from the TRIALPANORAMA database. The benchmark spans eight tasks across two categories: three for systematic review (study search, study screening, and evidence summarization) and five for trial design (arm design, eligibility criteria, endpoint selection, sample size estimation, and trial completion assessment). The experiments using five state-of-the-art large language models (LLMs) show that while general-purpose LLMs exhibit some zero-shot capability, their performance is still inadequate for high-stakes clinical trial workflows. We release TRIALPANORAMA database and the benchmark to facilitate further research on AI for clinical trials.

## 1 Introduction

Developing new drugs is a time-consuming and costly endeavor, often requiring up to a decade and exceeding \$2 billion in expenses [1]. A substantial portion of this burden stems from the human study phase, during which clinical trials are conducted to assess safety and efficacy across phases I through IV. In addition, clinicians, researchers, and trial designers routinely search and review clinical trial records and results. These efforts support critical objectives such as designing new trials, evaluating treatments, and informing clinical decision-making in evidence-based medicine [2, 3].

Clinical trial records are dispersed across global registries, including ClinicalTrials.gov [4], the International Clinical Trials Registry Platform (ICTRP) [5], the EU Clinical Trials Register [6], and others [7, 8]. Additionally, many trials are reported in the literature, particularly on PubMed. Prior research has focused on curating subsets of this data for specific objectives, such as clinical trial results [9, 10], drug and condition annotations [11, 12], trial-publication linkages [13], and structured outcomes [14]. A unified view that integrates these diverse aspects of clinical trial data can substantially improve evidence synthesis in systematic reviews and enable more informed, data-driven

Table 1: Comparison of TRIALPANORAMA and prior clinical trial datasets and benchmarks. Columns: Size = dataset size (# trials), Src = data source (CTG = ClinicalTrials.gov), Des = structured trial design data (e.g., arms, eligibility), Res = structured trial results (e.g., adverse events), Out = trial outcomes, Rel = trial-study/publication/review relations, Ont = linked to medical ontologies (e.g., DrugBank, MedDRA), Bench-D = trial design benchmark tasks, Bench-SLR = systematic literature review benchmark tasks.

Dataset / Benchmark	Size	Src	Des	Res	Out	Rel	Ont	Bench-D	Bench-SLR
TRIALPANORAMA (Ours)	1.6M	Multi(15 sources)	✓	✓	✓	✓	✓	✓	✓
TOP [19]	10K	CTG	✗	✗	✓	✗	✗	✓	✗
CTKG [11]	8K	CTG	✓	✗	✓	✗	✓	✗	✗
CTGResults [9]	56K	CTG	✗	✗	✓	✗	✗	✗	✗
CTO [14]	125K	CTG	✗	✓	✓	✗	✗	✗	✗
TrialBench [30]	400K	CTG	✓	✗	✓	✗	✓	✓	✗
CARE [10]	700 pubs	PubMed	✗	✗	✓	✗	✗	✗	✗
PubMedKG [31]	480K	PubMed,CTG	✗	✗	✗	✓	✗	✗	✗
TrialReviewBench [28]	100 reviews	PubMed,CTG	✗	✗	✗	✓	✗	✗	✓
LEADSInstruct [27]	21K reviews	PubMed,CTG	✗	✗	✗	✓	✗	✗	✓

approaches to designing future clinical trials [15–17]. In this work, we build TRIALPANORAMA, a clinical trial database that integrates multiple data sources and standardizes trial-level design and result attributes, aiming to provide a great resource for clinical trial design and review as well as developing AI models for these tasks.

Artificial intelligence (AI), particularly with the emergence of large language models (LLMs), has garnered significant attention in clinical trial applications. Recent advances have explored tasks including predicting clinical trial outcomes [18–20], matching patients to eligible trials [21, 22], extracting cohort real-world data [23, 24], writing clinical trial documents [25, 26], and accelerating systematic review of the literature of clinical studies [27, 28]. However, these developments are often limited by the lack of standardized, comprehensive clinical trial data suitable for AI development. TRIALPANORAMA bridges this gap by (1) offering curated benchmark data to support the development and evaluation of AI methods for trial applications, and (2) providing source-grounded evidence to enhance AI for trial applications through retrieval-augmented generation (RAG) [29].

In this work, we introduce TRIALPANORAMA, the largest-to-date structured clinical trial database, integrating over two million records from 16 global sources, including clinical trial registries, biomedical literature, and systematic reviews. As illustrated in Figure 1a, the database captures essential elements of clinical trials, such as study designs, interventions, conditions, outcomes, and biomarkers, and standardizes them through mappings to biomedical ontologies like DrugBank and MedDRA.

Building on this data foundation, we further demonstrate how TRIALPANORAMA enables tasks that support AI development for trial design and systematic review. These tasks span both upstream evidence synthesis (e.g., study search, screening, summarization) and downstream trial planning (e.g., arm design, eligibility criteria, endpoint selection, sample size estimation, and trial completion prediction), as illustrated in Figures 1b and 1c. Compared to existing trial datasets and benchmarks (Table 1), TRIALPANORAMA offers broader coverage, richer structure, and stronger alignment with real-world AI use cases in clinical research. We release the database and benchmark to facilitate future research in this space.

## 2 TRIALPANORAMA: Database

As illustrated in Figure 1a, the TRIALPANORAMA database comprises ten main tables: studies, conditions, drugs, endpoints, relations, biomarkers, outcomes, adverse events, results, and relations. These tables are organized into four conceptual clusters: trial attributes, trial protocols, trial results, and study-level links. The trial metadata cluster captures core metadata such as study title, brief summary, sponsor, start year, and recruitment status. The trial protocol cluster describes the setup and design of the study, including tested drugs, targeted conditions, and patient group allocations. The trial results cluster encompasses reported findings, including the trial outcomes, adverse events, and efficacy results. The study-level link cluster encodes relationships across studies, such as mappings between registry records and corresponding publications, or reviews aggregating multiple studies on a common clinical topic. In the following subsections, we describe




Figure 1: Overview of the TRIALPANORAMA dataset and benchmark suite. (a) Schema of the structured clinical trial database, showing linked tables for trial protocols, interventions, outcomes, and metadata. (b) Summary of the systematic review benchmark tasks. (c) Summary of the clinical trial design benchmark tasks.

the content of each table in detail. Data acquisition and processing procedures are provided in Appendix A.

## 2.1 Trial metadata

The studies table serves as the central registry in TRIALPANORAMA, containing 1,657,476 clinical trial records from 15 diverse sources, including ClinicalTrials.gov, PubMed, CHICTR, etc. The distribution of the sources is illustrated in Figure 2a. Each row, uniquely indexed by a study\_id, captures metadata such as trial type (INTERVENTIONAL, OBSERVATIONAL), sponsor (e.g., university, hospital, pharmaceutical), and temporal attributes including start\_year, enabling longitudinal analysis. The table also includes regulatory fields like phase (e.g., PHASE1–PHASE4) and recruitment status (e.g., RECRUITING, COMPLETED, SUSPENDED), providing a standardized overview of the trial’s attributes.

## 2.2 Trial protocols

The trial protocol cluster in TRIALPANORAMA captures structured information describing the design and setup of clinical studies, including target populations, interventions, outcomes, and biological markers. This cluster comprises five key tables: drugs, conditions, biomarkers, dispositions, and endpoints.

**Drugs.** The drugs table records the therapeutic interventions evaluated across trials, comprising 1,498,985 rows and 15 columns. Each entry is linked to a study\_id, with over 616,000 unique studies represented. The distribution of top frequent drugs is shown in Figure 2b. The drug\_name field captures 404,175 unique names, including both generic labels (e.g., “Placebo”) and brand/composite entries. To enable structured pharmacological analysis, drugs are linked to DrugBank identifiers (drugbank\_id) and normalized RxNorm terms (rx\_normalized\_name). Mechanism of action (MoA) information is encoded via the drug\_moa\_id field, which maps each drug to its biological






Figure 3: Manual data quality assessment across key database tables. The y-axis shows the proportion of valid (i.e., correctly extracted) records. Sample sizes (n) are shown below each bar.

annotations facilitate downstream analyses such as success rate estimation and status tracking across therapeutic areas and time.

**Results.** The `results` table comprises over 5.7 million entries covering more than 1.1 million studies. It records arm-level trial outcomes, including structured descriptions of study populations (`population`), tested interventions (`interventions`), observed clinical outcomes (`outcomes`), and treatment group type (`group_type`). The granularity of eligibility criteria and baseline characteristics captured in the `population` field supports fine-grained subgroup analysis, while the `group_type` distinction (e.g., *EXPERIMENTAL*, *COMPARATOR*) enables comparative outcome interpretation across arms.

**Adverse Events.** The `adverse_events` table documents reported safety events across 6,145,012 rows and over 530,000 unique studies. It captures `adverse_event_name` (e.g., *Headache*, *Nausea*, *Diarrhoea*) along with corresponding MedDRA-coded identifiers (`meddra_id`), enabling standardized aggregation and harmonization of safety profiles across studies. These data support pharmacovigilance and risk-benefit assessments for individual therapies or therapeutic classes.

## 2.4 Study links

The `relations` table captures cross-study relationships that connect clinical trial records from different sources or define higher-order linkages such as reviews or citation networks. This table contains 940,582 relation instances and supports integration, traceability, and synthesis of trial-level evidence. Each row represents a directed edge between a `head_id` and a `tail_id`, with associated `head_type` and `tail_type` identifying the origin of the studies (e.g., *PubMed*, *ClinicalTrials.gov*, or regional registries). This structure allows the database to represent connections between registry entries and publications describing the same study, or group related records across different national databases. The semantic type of each link is encoded in the `relation_type` field, which includes labels such as *linked\_to* (e.g., registry-publication pair), *cite* (e.g., PubMed-to-PubMed citation), *include* (e.g., a review including a trial), and *exclude* (e.g., a review explicitly excluding a study). These relationships enable downstream use cases such as study clustering, citation graph construction, and synthesis of trial networks for systematic reviews.

## 2.5 Data quality assessment

To assess the quality of TRIALPANORAMA, we employed seven annotators to manually verify approximately 1,500 records sampled across all major tables, stratified by data sources. Each sampled record was evaluated against the original source to determine its validity. As summarized in Figure 3, the database exhibits high overall accuracy, with most tables showing a validity rate above 90%. Notably, errors observed in some tables, particularly `conditions` and `biomarkers`, can be attributed to challenges in text-based pattern matching and the use of LLMs for information extraction. Despite

these limitations, the results highlight the feasibility and promise of using LLMs to automatically structure clinical trial data from heterogeneous and unstructured sources.

### 3 TRIALPANORAMA: Benchmark

TRIALPANORAMA serves as a valuable resource for a wide range of clinical trial applications by offering a global view of trial protocols, outcomes, and systematic reviews. Building on this comprehensive foundation, we develop a suite of representative benchmark tasks spanning two key application areas: three tasks focused on systematic evidence synthesis and five tasks supporting data-driven clinical trial design. These benchmarks are illustrated in Figures 1b and 1c.

#### 3.1 Systematic review tasks

The PRISMA statement [32] outlines standard procedures for conducting systematic reviews and meta-analyses in medicine. Among these, three critical steps are: (1) study search: identifying candidate studies from literature databases; (2) study screening: selecting eligible studies based on inclusion and exclusion criteria; and (3) evidence synthesis: aggregating findings from included studies to answer a targeted clinical question, such as the efficacy of a therapy for a specific condition. Based on TRIALPANORAMA, we construct benchmark tasks corresponding to each of these key steps: *study search*, *study screening*, and *evidence summarization*. By leveraging the `relations` table, we are able to identify linkages between systematic review articles and the clinical trials they include or exclude, enabling the construction of high-quality, labeled benchmarks for these tasks. We hold the most recent studies and reviews out as the test set. The details of benchmark building, setups, and example samples are in Appendix B.

**Study Search.** The study search task evaluates an AI model’s ability to retrieve relevant clinical trials from a large corpus, given the structured context of a systematic review. It simulates the first PRISMA step: identifying candidate studies based on a review’s topic. Each benchmark instance includes a query review defined by its background, objectives, and selection criteria, and models must retrieve trials that were included in the final review. Ground-truth labels are derived from the `relations` table in TRIALPANORAMA. The benchmark includes 8,004 training reviews linked to 175,577 studies and 100 test reviews with 4,324 relevant studies. Retrieval performance is measured using Recall@K.

**Study Screening.** The study screening task evaluates an AI model’s ability to determine whether candidate studies meet the inclusion criteria of a systematic review, simulating the second PRISMA step of study selection. Each benchmark instance includes a structured review query (background, objectives, and criteria) and 10 candidate studies described by both unstructured text (title and abstract) and structured metadata from TRIALPANORAMA (e.g., phase, intervention, conditions). Ground-truth labels are derived from explicit inclusion/exclusion links in the `relations` table. Notably, the excluded candidates represent hard negatives, as they were manually excluded by the original review authors and recorded in the review’s study list. The benchmark includes 7,931 training reviews with over 175,000 included and 229,000 excluded studies, and 100 test reviews with 491 included and 488 excluded studies. Performance is evaluated using accuracy, precision, and recall.

**Evidence Summarization.** The evidence summarization task evaluates an AI model’s ability to answer clinical research questions by synthesizing findings from relevant studies, emulating the last PRISMA step: evidence summarization. Each instance includes (1) the review’s structured setup (background, objectives, selection criteria), (2) a set of study abstracts containing relevant or irrelevant evidence, and (3) a multiple-choice question summarizing possible conclusions. Input data and gold labels are constructed using the `relations` and `results` tables in TRIALPANORAMA, where study-review links define the context and structured trial findings inform the correct answer. Answer choices reflect typical clinical conclusions (e.g., “limited evidence” or “effective with adverse effects”). The benchmark contains 4,636 reviews and 35,512 studies in the training set, and 1,000 reviews with 8,974 studies in the test set. Model performance is assessed using accuracy and macro-F1 score.



### 3.2 Clinical trial design tasks

Designing a clinical trial involves multiple interdependent components that collectively determine its scientific validity and operational feasibility. As illustrated in Figure 1c, key design tasks include: (1) *sample size estimation*, which determines the number of participants needed to ensure sufficient statistical power to detect treatment effects; (2) *eligibility criteria design*, which defines the characteristics of the target population eligible for inclusion; (3) *arm design*, which specifies the allocation of participants into treatment and control groups with defined interventions; and (4) *endpoint design*, which identifies the clinical measures used to assess efficacy and safety. In addition, *trial completion assessment* evaluates whether a trial is likely to reach completion or be terminated early due to design flaws, recruitment challenges, or safety concerns, thus providing a holistic perspective on the robustness of the trial design. We hold the most recent studies out as the test set. The details of benchmark building, setups, and example samples are in Appendix C.

**Arm, Eligibility Criteria, and Endpoint Design.** The trial design tasks assess a model’s ability to identify optimal design components for a given trial protocol. Each task presents a structured input, consisting of the trial’s title and brief summary, and asks the model to select the correct choice from a set of candidate design elements, where distractors are sampled from similar trials to ensure difficulty. In the arm design task, the goal is to select the correct configuration of intervention groups; in eligibility criteria design, the correct inclusion and exclusion conditions; and in endpoint design, the appropriate outcome measures. Candidate options are drawn from structured records in TRIALPANORAMA, including data from the studies, dispositions, conditions, and endpoints tables. For all three tasks, performance is evaluated using classification accuracy. The benchmark includes 27,321 training studies and 1,000 test studies for each of the three tasks.

**Sample Size Estimation.** The sample size estimation task evaluates a model’s ability to infer the required number of participants for a clinical trial, based on its structured protocol, including target conditions, interventions, and primary outcomes, under a fixed drop-out assumption. Each instance draws data from the studies, dispositions, and endpoints tables in TRIALPANORAMA, paired with gold-standard target values extracted from protocols or publications. The benchmark includes 1,143 training examples and 1,000 test studies. Model performance is assessed using two metrics: accuracy (percentage of estimation within  $\pm 20\%$  of ground truth) and mean absolute error (MAE). This task requires both clinical reasoning and quantitative estimation skills grounded in trial design logic.

**Trial Completion Assessment.** This task evaluates a model’s ability to predict whether a clinical trial will reach completion or terminate early based on its protocol, and, if terminated, to identify the most likely reason (e.g., efficacy, safety, enrollment failure). Each instance includes structured trial metadata, such as study phase, arm count, masking, allocation, and eligibility criteria, drawn from the studies, dispositions, and results tables in TRIALPANORAMA. The benchmark comprises 42,195 training studies and 1,000 test studies. Model performance is evaluated by balanced accuracy on (1) the binary completion prediction and (2) multiclass termination reason classification. This task reflects real-world feasibility assessments during trial planning.

## 4 Experiment

We selected a diverse set of state-of-the-art proprietary and open-source LLMs for evaluation. These include GPT-4o and its lightweight variant GPT-4o-mini, as well as the recent reasoning-focused model O3-mini, all accessed via the Azure OpenAI Service. In addition, we include the LLaMA-3.3-70B-Instruct and LLaMA-3.1-8B-Instruct models, representing large and moderate-scale open-source LLMs, accessed through the Azure AI Inference Service. This selection allows us to compare models across different scales, architectures, and reasoning capabilities.

### 4.1 Systematic review tasks

Table 2 presents the performance of various LLMs across three core systematic review tasks: study search, study screening, and evidence summarization. The results highlight both general limitations and comparative strengths across models. First, performance on the study search task is uniformly low, with Recall@100 ranging from 11.6 (LLaMA-8B) to 27.6 (O3-mini). This reflects a key weakness

Table 2: Benchmark experiment results for systematic review tasks.

Tasks Models	Study search		Study screening			Evidence summarization	
	Recall@100	Recall@500	Accuracy	Precision	Recall	Accuracy	Macro-F1
Llama-8B	11.6	16.0	55.3	46.8	58.2	70.4	71.1
Llama-70B	25.1	33.3	60.7	59.1	70.5	<b>78.8</b>	<b>76.7</b>
GPT-4o-mini	17.3	22.7	60.2	60.4	60.5	74.1	73.1
GPT-4o	22.9	27.3	66.1	64.4	<b>72.3</b>	72.8	65.2
O3-mini	<b>27.6</b>	<b>37.8</b>	<b>71.6</b>	<b>71.9</b>	71.3	72.7	53.8

Table 3: Benchmark experiment results for clinical trial design tasks. “Acc”: short for accuracy; “BAcc-out”: short for balanced accuracy of trial outcome assessment results; “BAcc-rt”: short for balanced accuracy of trial termination rationalization results; “MAE ↓”: mean absolute error that is the smaller the better.

Tasks Models	Arm design		Eligibility criteria design		Endpoint design		Sample size estimation		Trial completion	
	Acc	Macro-F1	Acc	Macro-F1	Acc	Macro-F1	Acc	MAE ↓	BAcc-out	BAcc-rt
Llama-8B	79.9	79.9	55.0	54.6	52.1	52.9	3.3	1760.6	54.0	15.7
Llama-70B	84.6	84.7	72.6	73.1	61.8	62.5	18.7	633.3	52.6	17.9
GPT-4o-mini	78.4	78.7	55.8	55.8	62.2	62.2	22.8	<b>411.4</b>	51.3	16.8
GPT-4o	85.0	85.0	76.3	76.5	<b>69.1</b>	<b>69.4</b>	22.9	512.6	<b>59.3</b>	<b>19.5</b>
O3-mini	<b>85.9</b>	<b>86.1</b>	<b>80.4</b>	<b>80.6</b>	52.1	60.7	<b>25.2</b>	452.1	51.0	17.0

of general-purpose LLMs: they struggle to generate precise and discriminative search queries that can retrieve relevant trials from a large corpus. Notably, O3-mini outperforms both proprietary (GPT-4o, GPT-4o-mini) and open-source (LLaMA-70B, LLaMA-8B) models by a significant margin, suggesting its reasoning-focused training may better align with the query formulation challenge.

Second, study screening performance is moderate, with accuracy scores ranging from 55.3 (LLaMA-8B) to 71.6 (O3-mini). The task is intrinsically difficult, as the negative examples in the test set are hard negatives. These studies are closely related to the review but were explicitly excluded by the original systematic review authors. Despite this challenge, O3-mini demonstrates the strongest overall performance in accuracy, precision, and recall, followed by GPT-4o. LLaMA-70B shows reasonable performance, while LLaMA-8B significantly underperforms.

Third, in evidence summarization, model performance varies more widely. LLaMA-70B achieves the highest accuracy (78.8) and Macro-F1 (76.7), outperforming GPT-4o and GPT-4o-mini, which show moderately strong but less consistent results. Surprisingly, O3-mini, which performs best on study search and screening, shows notably weak performance in summarization (Macro-F1 = 53.8), despite being positioned as a reasoning-oriented model. This result is somewhat counterintuitive, as reasoning-capable models are typically expected to excel at inference tasks that involve aggregating evidence from multiple sources.

## 4.2 Clinical trial design tasks

Table 3 presents the evaluation of LLMs across five clinical trial design tasks. First, arm design appears to be the easiest among the structured design tasks, with all models achieving relatively high accuracy and macro-F1. O3-mini achieves the highest scores (85.9 accuracy and 86.1 macro-F1), followed closely by GPT-4o, suggesting that LLMs are generally capable of recovering structured intervention information when explicitly described in the trial protocol.

In contrast, endpoint design proves to be more challenging. All models perform worse on this task, with accuracy ranging from 52.1 to 69.1 and lower macro-F1 across the board. The relatively poor performance, even among advanced models like GPT-4o and O3-mini. Second, sample size estimation remains a particularly difficult task for all models. Despite the reasoning-oriented nature of the problem, no model achieves an accuracy above 26%, and mean absolute error (MAE) remains high for all (e.g., 411.4 for GPT-4o-mini and 452.1 for O3-mini). This indicates that LLMs, even those designed for reasoning, lack the statistical grounding or calibration mechanisms required to estimate participant counts from trial parameters such as design type, treatment arms, and expected effect size. Third, trial completion assessment is also highly challenging. Performance on binary outcome prediction (whether a trial is completed or terminated) and termination rationale identification appears



near random, with balanced accuracy scores clustered around 50–55% for trial status (BAcc-out) and 15–20% for termination reasoning (BAcc-rt). This reflects the difficulty of inferring future feasibility outcomes from trial protocols.

In a nutshell, these results indicate that current general-purpose LLMs fall short in supporting key trial design decisions. While they show some promise in recognizing explicit design elements, they are far less reliable for tasks that require statistical reasoning, feasibility forecasting, or context-aware endpoint selection. These gaps highlight the need for further research and specialized model development for clinical trial tasks.

## 5 Related work

Several recent efforts have focused on constructing structured datasets and benchmarks for clinical trials. TOP [19] introduced a benchmark for clinical trial outcome prediction with approximately 10K trials, while TrialBench [30] expanded to include 400K trials from ClinicalTrials.gov for predicting trial duration, outcomes, and other attributes. CTKG [11] proposed a knowledge graph that captures design entities (e.g., drugs, conditions) from 8K trials, and FinegrainedResults [9] structured 56K trials into arm-level result graphs. CTO [14] similarly focused on representing outcome data for 125K interventional trials. CARE [10] extracted structured trial results from 700 literature publications, while PubMedKG [31] linked trial identifiers and citations across publications, patents, and trial registries. Other lines of work have developed benchmarks for systematic literature review (SLR) tasks. TrialReviewBench [28] built a benchmark with 100 systematic reviews for study search, screening, and evidence summarization, and LEADSInstruct [27] scaled these efforts to 21K reviews. However, most of these datasets are limited in scope, focusing only on trials’ design or results, lacking ontology alignment, or without accompanying benchmark tasks. Our work, TRIALPANORAMA, addresses these limitations by unifying trial records from 16 global sources and linking them to biomedical ontologies. It supports both structured design and result representations, and enables a broad suite of benchmark tasks for both trial design and systematic review automation.

## 6 Discussion and conclusion

Despite the broad coverage and structured integration of clinical trial data in TRIALPANORAMA, several limitations should be acknowledged. First, the dataset may reflect biases introduced by the data collection process itself. For instance, trials registered on ClinicalTrials.gov, primarily based in the United States, are more consistently structured and accessible than those from other countries, potentially leading to overrepresentation of U.S.-centric studies or specific trial designs. Similarly, trial information extracted from scientific publications relies on unstructured text, which varies in quality and completeness and may introduce processing bias. Second, there is inherent selection bias in the publication landscape, where studies with positive outcomes are more likely to be published, skewing the dataset’s representation of trial attributes and results. Third, while LLMs were employed to assist in data extraction and have demonstrated promising accuracy based on sampled validation, systematic evaluation and error mitigation remain areas for future improvement to ensure high data fidelity across the entire dataset. Lastly, the benchmark data constructed in this work represents a simplified and task-focused abstraction of real-world clinical trial workflows. It does not capture the full complexity and variability of trial design and execution. In addition, the selected LLMs and baseline methods evaluated here reflect only a subset of possible approaches; further exploration of model variants, the role of memorization, and prospective evaluation settings will be important for understanding generalizability and real-world utility.

To summarize, we presented TRIALPANORAMA, a large-scale structured database of clinical trials, along with a benchmark of eight tasks for systematic review and trial design. Evaluation of five leading LLMs reveals limited performance, highlighting the need for domain-adapted AI systems in clinical research. TRIALPANORAMA provides a foundation to support future development of intelligent tools for clinical trial planning, evidence synthesis, and automation.

## References

- [1] Linda Martin, Melissa Hutchens, Conrad Hawkins, and Alaina Radnov. How much do clinical trials cost? *Nature Reviews Drug Discovery*, 16(6):381–382, 2017.

- [2] Andy P Field and Raphael Gillett. How to do a meta-analysis. *British Journal of Mathematical and Statistical Psychology*, 63(3):665–694, 2010.
- [3] John Concato, Nirav Shah, and Ralph I Horwitz. Randomized, controlled trials, observational studies, and the hierarchy of research designs. In *Research Ethics*, pages 207–212. Routledge, 2017.
- [4] Clinicaltrials.gov is a place to learn about clinical studies from around the world. <https://clinicaltrials.gov/>. Accessed: 2025-05-01.
- [5] International clinical trials registry platform (ictrp). <https://www.who.int/tools/clinical-trials-registry-platform>. Accessed: 2025-05-01.
- [6] Eu clinical trials register. <https://www.clinicaltrialsregister.eu/about.html>. Accessed: 2025-05-01.
- [7] Australian new zealand clinical trials registry. <https://www.anzctr.org.au/>. Accessed: 2025-05-01.
- [8] Chinese clinical trial registry. <https://www.chictr.org.cn/indexEN.html>. Accessed: 2025-05-01.
- [9] Xuanyu Shi and Jian Du. Constructing a finer-grained representation of clinical trial results from clinicaltrials. gov. *Scientific Data*, 11(1):41, 2024.
- [10] Aakanksha Naik, Bailey Kuehl, Erin Bransom, Doug Downey, and Tom Hope. Care: Extracting experimental findings from clinical literature. In *Findings of the Association for Computational Linguistics: NAACL 2024*, pages 4580–4596, 2024.
- [11] Ziqi Chen, Bo Peng, Vassilis N Ioannidis, Mufei Li, George Karypis, and Xia Ning. A knowledge graph of clinical trials (ctkg). *Scientific reports*, 12(1):4724, 2022.
- [12] Maria Brbić, Michihiro Yasunaga, Prabhat Agarwal, and Jure Leskovec. Predicting drug outcome of population via clinical knowledge graph. *medRxiv*, 2024.
- [13] Jian Xu, Sunkyu Kim, Min Song, Minbyul Jeong, Donghyeon Kim, Jaewoo Kang, Justin F Rousseau, Xin Li, Weijia Xu, Vette I Torvik, et al. Building a pubmed knowledge graph. *Scientific data*, 7(1):205, 2020.
- [14] Chufan Gao, Jathurshan Pradeepkumar, Trisha Das, Shivashankar Thati, and Jimeng Sun. Automatically labeling \$200 b life-saving datasets: A large clinical trial outcome benchmark. *arXiv preprint arXiv:2406.10292*, 2024.
- [15] Adam G Dunn and Florence T Bourgeois. Is it time for computable evidence synthesis? *Journal of the American Medical Informatics Association*, 27(6):972–975, 2020.
- [16] Björn Holzhauer and Emmanuel Taiwo Adewuyi. Super-covariates: Using predicted control group outcome as a covariate in randomized clinical trials. *Pharmaceutical Statistics*, 22(6): 1062–1075, 2023.
- [17] Edward S Kim, Suanna S Bruinooge, Samantha Roberts, Gwynn Ison, Nancy U Lin, Lia Gore, Thomas S Uldrick, Stuart M Lichtman, Nancy Roach, Julia A Beaver, et al. Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement. *Journal of Clinical Oncology*, 35(33):3737–3744, 2017.
- [18] Qiao Jin, Chuanqi Tan, Mosha Chen, Xiaozhong Liu, and Songfang Huang. Predicting clinical trial results by implicit evidence integration. In *Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing (EMNLP)*, pages 1461–1477, 2020.
- [19] Tianfan Fu, Kexin Huang, Cao Xiao, Lucas M Glass, and Jimeng Sun. Hint: Hierarchical interaction network for clinical-trial-outcome predictions. *Patterns*, 3(4), 2022.

- [20] Zifeng Wang, Cao Xiao, and Jimeng Sun. Spot: Sequential predictive modeling of clinical trial outcome with meta-learning. In *Proceedings of the 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics*, pages 1–11, 2023.
- [21] Qiao Jin, Zifeng Wang, Charalampos S Floudas, Fangyuan Chen, Changlin Gong, Dara Bracken-Clarke, Elisabetta Xue, Yifan Yang, Jimeng Sun, and Zhiyong Lu. Matching patients to clinical trials with large language models. *Nature Communications*, 15(1):9074, 2024.
- [22] Michael Wornow, Alejandro Lozano, Dev Dash, Jenelle Jindal, Kenneth W Mahaffey, and Nigam H Shah. Zero-shot clinical trial patient matching with llms. *NEJM AI*, 2(1):AIcs2400360, 2025.
- [23] Chi Yuan, Patrick B Ryan, Casey Ta, Yixuan Guo, Ziran Li, Jill Hardin, Rupa Makadia, Peng Jin, Ning Shang, Tian Kang, et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. *Journal of the American Medical Informatics Association*, 26(4):294–305, 2019.
- [24] Jimyung Park, Yilu Fang, Casey Ta, Gongbo Zhang, Betina Idnay, Fangyi Chen, David Feng, Rebecca Shyu, Emily R Gordon, Matthew Spotnitz, et al. Criteria2Query 3.0: Leveraging generative large language models for clinical trial eligibility query generation. *Journal of Biomedical Informatics*, 154:104649, 2024.
- [25] Zifeng Wang, Cao Xiao, and Jimeng Sun. Autotrial: Prompting language models for clinical trial design. In *Proceedings of the 2023 Conference on Empirical Methods in Natural Language Processing*, pages 12461–12472, 2023.
- [26] Zifeng Wang, Junyi Gao, Benjamin Danek, Brandon Theodorou, Ruba Shaik, Shivashankar Thati, Seunghyun Won, and Jimeng Sun. Informgen: An ai copilot for accurate and compliant clinical research consent document generation. *arXiv preprint arXiv:2504.00934*, 2025.
- [27] Zifeng Wang, Lang Cao, Qiao Jin, Joey Chan, Nicholas Wan, Behdad Afzali, Hyun-Jin Cho, Chang-In Choi, Mehdi Emamverdi, Manjot K Gill, et al. A foundation model for human-ai collaboration in medical literature mining. *arXiv preprint arXiv:2501.16255*, 2025.
- [28] Zifeng Wang, Lang Cao, Benjamin Danek, Qiao Jin, Zhiyong Lu, and Jimeng Sun. Accelerating clinical evidence synthesis with large language models. *arXiv preprint arXiv:2406.17755*, 2024.
- [29] Patrick Lewis, Ethan Perez, Aleksandra Piktus, Fabio Petroni, Vladimir Karpukhin, Naman Goyal, Heinrich Küttler, Mike Lewis, Wen-tau Yih, Tim Rocktäschel, et al. Retrieval-augmented generation for knowledge-intensive nlp tasks. *Advances in Neural Information Processing Systems*, 33:9459–9474, 2020.
- [30] Jintai Chen, Yaojun Hu, Yue Wang, Yingzhou Lu, Xu Cao, Miao Lin, Hongxia Xu, Jian Wu, Cao Xiao, Jimeng Sun, et al. Trialbench: Multi-modal artificial intelligence-ready clinical trial datasets. *arXiv preprint arXiv:2407.00631*, 2024.
- [31] Jian Xu, Chao Yu, Jiawei Xu, Ying Ding, Vette I Torvik, Jaewoo Kang, Mujeen Sung, and Min Song. Pubmed knowledge graph 2.0: Connecting papers, patents, and clinical trials in biomedical science. *arXiv preprint arXiv:2410.07969*, 2024.
- [32] Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*, 372, 2021.
- [33] Sorin Avram, Thomas B Wilson, Ramona Curpan, Liliana Halip, Ana Borota, Alina Bora, Cristian G Bologna, Jayme Holmes, Jeffrey Knockel, Jeremy J Yang, et al. Drugcentral 2023 extends human clinical data and integrates veterinary drugs. *Nucleic acids research*, 51(D1): D1276–D1287, 2023.
- [34] Yintao Zhang, Ying Zhou, Yuan Zhou, Xinyuan Yu, Xinyi Shen, Yanfeng Hong, Yuxin Zhang, Shanshan Wang, Minjie Mou, Jinsong Zhang, Lin Tao, Jianqing Gao, Yunqing Qiu, Yuzong Chen, and Feng Zhu. Themarker: a comprehensive database of therapeutic biomarkers. *Nucleic Acids Research*, 52(D1):D1450–D1464, 10 2023. ISSN 0305-1048. doi: 10.1093/nar/gkad862. URL <https://doi.org/10.1093/nar/gkad862>.

- [35] Susanna Dodd, Mike Clarke, Lorne Becker, Chris Mavergames, Rebecca Fish, and Paula R Williamson. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *Journal of clinical epidemiology*, 96:84–92, 2018.
- [36] Jamie J Kirkham and Paula Williamson. Core outcome sets in medical research. *BMJ medicine*, 1(1):e000284, 2022.

## NeurIPS Paper Checklist

### 1. Claims

Question: Do the main claims made in the abstract and introduction accurately reflect the paper's contributions and scope?

Answer: [\[Yes\]](#)

Justification: [\[NA\]](#)

Guidelines:

- The answer NA means that the abstract and introduction do not include the claims made in the paper.
- The abstract and/or introduction should clearly state the claims made, including the contributions made in the paper and important assumptions and limitations. A No or NA answer to this question will not be perceived well by the reviewers.
- The claims made should match theoretical and experimental results, and reflect how much the results can be expected to generalize to other settings.
- It is fine to include aspirational goals as motivation as long as it is clear that these goals are not attained by the paper.

### 2. Limitations

Question: Does the paper discuss the limitations of the work performed by the authors?

Answer: [\[Yes\]](#)

Justification: [\[NA\]](#)

Guidelines:

- The answer NA means that the paper has no limitation while the answer No means that the paper has limitations, but those are not discussed in the paper.
- The authors are encouraged to create a separate "Limitations" section in their paper.
- The paper should point out any strong assumptions and how robust the results are to violations of these assumptions (e.g., independence assumptions, noiseless settings, model well-specification, asymptotic approximations only holding locally). The authors should reflect on how these assumptions might be violated in practice and what the implications would be.
- The authors should reflect on the scope of the claims made, e.g., if the approach was only tested on a few datasets or with a few runs. In general, empirical results often depend on implicit assumptions, which should be articulated.
- The authors should reflect on the factors that influence the performance of the approach. For example, a facial recognition algorithm may perform poorly when image resolution is low or images are taken in low lighting. Or a speech-to-text system might not be used reliably to provide closed captions for online lectures because it fails to handle technical jargon.
- The authors should discuss the computational efficiency of the proposed algorithms and how they scale with dataset size.
- If applicable, the authors should discuss possible limitations of their approach to address problems of privacy and fairness.
- While the authors might fear that complete honesty about limitations might be used by reviewers as grounds for rejection, a worse outcome might be that reviewers discover limitations that aren't acknowledged in the paper. The authors should use their best judgment and recognize that individual actions in favor of transparency play an important role in developing norms that preserve the integrity of the community. Reviewers will be specifically instructed to not penalize honesty concerning limitations.

### 3. Theory assumptions and proofs

Question: For each theoretical result, does the paper provide the full set of assumptions and a complete (and correct) proof?

Answer: [\[NA\]](#)

Justification: This paper does not involve theoretical results.

Guidelines:

- The answer NA means that the paper does not include theoretical results.
- All the theorems, formulas, and proofs in the paper should be numbered and cross-referenced.
- All assumptions should be clearly stated or referenced in the statement of any theorems.
- The proofs can either appear in the main paper or the supplemental material, but if they appear in the supplemental material, the authors are encouraged to provide a short proof sketch to provide intuition.
- Inversely, any informal proof provided in the core of the paper should be complemented by formal proofs provided in appendix or supplemental material.
- Theorems and Lemmas that the proof relies upon should be properly referenced.

#### 4. Experimental result reproducibility

Question: Does the paper fully disclose all the information needed to reproduce the main experimental results of the paper to the extent that it affects the main claims and/or conclusions of the paper (regardless of whether the code and data are provided or not)?

Answer: [\[Yes\]](#)

Justification: [\[NA\]](#)

Guidelines:

- The answer NA means that the paper does not include experiments.
- If the paper includes experiments, a No answer to this question will not be perceived well by the reviewers: Making the paper reproducible is important, regardless of whether the code and data are provided or not.
- If the contribution is a dataset and/or model, the authors should describe the steps taken to make their results reproducible or verifiable.
- Depending on the contribution, reproducibility can be accomplished in various ways. For example, if the contribution is a novel architecture, describing the architecture fully might suffice, or if the contribution is a specific model and empirical evaluation, it may be necessary to either make it possible for others to replicate the model with the same dataset, or provide access to the model. In general, releasing code and data is often one good way to accomplish this, but reproducibility can also be provided via detailed instructions for how to replicate the results, access to a hosted model (e.g., in the case of a large language model), releasing of a model checkpoint, or other means that are appropriate to the research performed.
- While NeurIPS does not require releasing code, the conference does require all submissions to provide some reasonable avenue for reproducibility, which may depend on the nature of the contribution. For example
  - (a) If the contribution is primarily a new algorithm, the paper should make it clear how to reproduce that algorithm.
  - (b) If the contribution is primarily a new model architecture, the paper should describe the architecture clearly and fully.
  - (c) If the contribution is a new model (e.g., a large language model), then there should either be a way to access this model for reproducing the results or a way to reproduce the model (e.g., with an open-source dataset or instructions for how to construct the dataset).
  - (d) We recognize that reproducibility may be tricky in some cases, in which case authors are welcome to describe the particular way they provide for reproducibility. In the case of closed-source models, it may be that access to the model is limited in some way (e.g., to registered users), but it should be possible for other researchers to have some path to reproducing or verifying the results.

#### 5. Open access to data and code

Question: Does the paper provide open access to the data and code, with sufficient instructions to faithfully reproduce the main experimental results, as described in supplemental material?



Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that paper does not include experiments requiring code.
- Please see the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- While we encourage the release of code and data, we understand that this might not be possible, so “No” is an acceptable answer. Papers cannot be rejected simply for not including code, unless this is central to the contribution (e.g., for a new open-source benchmark).
- The instructions should contain the exact command and environment needed to run to reproduce the results. See the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- The authors should provide instructions on data access and preparation, including how to access the raw data, preprocessed data, intermediate data, and generated data, etc.
- The authors should provide scripts to reproduce all experimental results for the new proposed method and baselines. If only a subset of experiments are reproducible, they should state which ones are omitted from the script and why.
- At submission time, to preserve anonymity, the authors should release anonymized versions (if applicable).
- Providing as much information as possible in supplemental material (appended to the paper) is recommended, but including URLs to data and code is permitted.

#### 6. Experimental setting/details

Question: Does the paper specify all the training and test details (e.g., data splits, hyper-parameters, how they were chosen, type of optimizer, etc.) necessary to understand the results?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not include experiments.
- The experimental setting should be presented in the core of the paper to a level of detail that is necessary to appreciate the results and make sense of them.
- The full details can be provided either with the code, in appendix, or as supplemental material.

#### 7. Experiment statistical significance

Question: Does the paper report error bars suitably and correctly defined or other appropriate information about the statistical significance of the experiments?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not include experiments.
- The authors should answer "Yes" if the results are accompanied by error bars, confidence intervals, or statistical significance tests, at least for the experiments that support the main claims of the paper.
- The factors of variability that the error bars are capturing should be clearly stated (for example, train/test split, initialization, random drawing of some parameter, or overall run with given experimental conditions).
- The method for calculating the error bars should be explained (closed form formula, call to a library function, bootstrap, etc.)
- The assumptions made should be given (e.g., Normally distributed errors).
- It should be clear whether the error bar is the standard deviation or the standard error of the mean.

- It is OK to report 1-sigma error bars, but one should state it. The authors should preferably report a 2-sigma error bar than state that they have a 96% CI, if the hypothesis of Normality of errors is not verified.
- For asymmetric distributions, the authors should be careful not to show in tables or figures symmetric error bars that would yield results that are out of range (e.g. negative error rates).
- If error bars are reported in tables or plots, The authors should explain in the text how they were calculated and reference the corresponding figures or tables in the text.

#### 8. Experiments compute resources

Question: For each experiment, does the paper provide sufficient information on the computer resources (type of compute workers, memory, time of execution) needed to reproduce the experiments?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not include experiments.
- The paper should indicate the type of compute workers CPU or GPU, internal cluster, or cloud provider, including relevant memory and storage.
- The paper should provide the amount of compute required for each of the individual experimental runs as well as estimate the total compute.
- The paper should disclose whether the full research project required more compute than the experiments reported in the paper (e.g., preliminary or failed experiments that didn't make it into the paper).

#### 9. Code of ethics

Question: Does the research conducted in the paper conform, in every respect, with the NeurIPS Code of Ethics <https://neurips.cc/public/EthicsGuidelines>?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the authors have not reviewed the NeurIPS Code of Ethics.
- If the authors answer No, they should explain the special circumstances that require a deviation from the Code of Ethics.
- The authors should make sure to preserve anonymity (e.g., if there is a special consideration due to laws or regulations in their jurisdiction).

#### 10. Broader impacts

Question: Does the paper discuss both potential positive societal impacts and negative societal impacts of the work performed?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that there is no societal impact of the work performed.
- If the authors answer NA or No, they should explain why their work has no societal impact or why the paper does not address societal impact.
- Examples of negative societal impacts include potential malicious or unintended uses (e.g., disinformation, generating fake profiles, surveillance), fairness considerations (e.g., deployment of technologies that could make decisions that unfairly impact specific groups), privacy considerations, and security considerations.
- The conference expects that many papers will be foundational research and not tied to particular applications, let alone deployments. However, if there is a direct path to any negative applications, the authors should point it out. For example, it is legitimate to point out that an improvement in the quality of generative models could be used to generate

deepfakes for disinformation. On the other hand, it is not needed to point out that a generic algorithm for optimizing neural networks could enable people to train models that generate Deepfakes faster.

- The authors should consider possible harms that could arise when the technology is being used as intended and functioning correctly, harms that could arise when the technology is being used as intended but gives incorrect results, and harms following from (intentional or unintentional) misuse of the technology.
- If there are negative societal impacts, the authors could also discuss possible mitigation strategies (e.g., gated release of models, providing defenses in addition to attacks, mechanisms for monitoring misuse, mechanisms to monitor how a system learns from feedback over time, improving the efficiency and accessibility of ML).

#### 11. Safeguards

Question: Does the paper describe safeguards that have been put in place for responsible release of data or models that have a high risk for misuse (e.g., pretrained language models, image generators, or scraped datasets)?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper poses no such risks.
- Released models that have a high risk for misuse or dual-use should be released with necessary safeguards to allow for controlled use of the model, for example by requiring that users adhere to usage guidelines or restrictions to access the model or implementing safety filters.
- Datasets that have been scraped from the Internet could pose safety risks. The authors should describe how they avoided releasing unsafe images.
- We recognize that providing effective safeguards is challenging, and many papers do not require this, but we encourage authors to take this into account and make a best faith effort.

#### 12. Licenses for existing assets

Question: Are the creators or original owners of assets (e.g., code, data, models), used in the paper, properly credited and are the license and terms of use explicitly mentioned and properly respected?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not use existing assets.
- The authors should cite the original paper that produced the code package or dataset.
- The authors should state which version of the asset is used and, if possible, include a URL.
- The name of the license (e.g., CC-BY 4.0) should be included for each asset.
- For scraped data from a particular source (e.g., website), the copyright and terms of service of that source should be provided.
- If assets are released, the license, copyright information, and terms of use in the package should be provided. For popular datasets, [paperswithcode.com/datasets](https://paperswithcode.com/datasets) has curated licenses for some datasets. Their licensing guide can help determine the license of a dataset.
- For existing datasets that are re-packaged, both the original license and the license of the derived asset (if it has changed) should be provided.
- If this information is not available online, the authors are encouraged to reach out to the asset's creators.

#### 13. New assets

Question: Are new assets introduced in the paper well documented and is the documentation provided alongside the assets?

Answer: [Yes]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not release new assets.
- Researchers should communicate the details of the dataset/code/model as part of their submissions via structured templates. This includes details about training, license, limitations, etc.
- The paper should discuss whether and how consent was obtained from people whose asset is used.
- At submission time, remember to anonymize your assets (if applicable). You can either create an anonymized URL or include an anonymized zip file.

#### 14. Crowdsourcing and research with human subjects

Question: For crowdsourcing experiments and research with human subjects, does the paper include the full text of instructions given to participants and screenshots, if applicable, as well as details about compensation (if any)?

Answer: [NA]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Including this information in the supplemental material is fine, but if the main contribution of the paper involves human subjects, then as much detail as possible should be included in the main paper.
- According to the NeurIPS Code of Ethics, workers involved in data collection, curation, or other labor should be paid at least the minimum wage in the country of the data collector.

#### 15. Institutional review board (IRB) approvals or equivalent for research with human subjects

Question: Does the paper describe potential risks incurred by study participants, whether such risks were disclosed to the subjects, and whether Institutional Review Board (IRB) approvals (or an equivalent approval/review based on the requirements of your country or institution) were obtained?

Answer: [NA]

Justification: [NA]

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Depending on the country in which research is conducted, IRB approval (or equivalent) may be required for any human subjects research. If you obtained IRB approval, you should clearly state this in the paper.
- We recognize that the procedures for this may vary significantly between institutions and locations, and we expect authors to adhere to the NeurIPS Code of Ethics and the guidelines for their institution.
- For initial submissions, do not include any information that would break anonymity (if applicable), such as the institution conducting the review.

#### 16. Declaration of LLM usage

Question: Does the paper describe the usage of LLMs if it is an important, original, or non-standard component of the core methods in this research? Note that if the LLM is used only for writing, editing, or formatting purposes and does not impact the core methodology, scientific rigor, or originality of the research, declaration is not required.

Answer: [NA]

Justification: [NA]

Guidelines:

- The answer NA means that the core method development in this research does not involve LLMs as any important, original, or non-standard components.
- Please refer to our LLM policy (<https://neurips.cc/Conferences/2025/LLM>) for what should or should not be described.

## Contents of Appendix

---

<b>A Database building</b>	<b>21</b>
A.1 Raw data collection . . . . .	21
A.2 Studies table . . . . .	21
A.3 Conditions table . . . . .	22
A.4 Drugs Table . . . . .	22
A.5 Trial results table . . . . .	24
A.6 Trial outcomes table . . . . .	24
A.7 Relations table . . . . .	26
A.8 Dispositions table . . . . .	27
A.9 Biomarkers table . . . . .	27
A.10 Endpoints table . . . . .	29
A.11 Adverse events table . . . . .	30
<b>B Benchmark building: Systematic review tasks</b>	<b>31</b>
B.1 Study search . . . . .	31
B.2 Study screening . . . . .	32
B.3 Evidence summarization . . . . .	33
<b>C Benchmark building: Trial design tasks</b>	<b>33</b>
C.1 Arm design . . . . .	33
C.2 Eligibility criteria design . . . . .	34
C.3 Endpoint design . . . . .	35
C.4 Sample size estimation . . . . .	36
C.5 Trial completion assessment . . . . .	37

---



## A Database building

### A.1 Raw data collection

To construct our benchmark dataset, we crawled clinical trial and publication records from a diverse set of publicly accessible registries and databases. The data URLs and the date of the most recent crawl are listed in Table 4.

Supplementary Table 4: List of data sources and the corresponding last crawl dates.

Source	Data URL	Last Crawled
ANZCTR	<a href="https://www.anzctr.org.au/">https://www.anzctr.org.au/</a>	April 1, 2025
Brazilian Registry	<a href="https://ensaioclinic.gov.br">https://ensaioclinic.gov.br</a>	April 1, 2025
ChiCTR	<a href="https://www.chictr.org.cn/searchprojEN.html">https://www.chictr.org.cn/searchprojEN.html</a>	April 1, 2025
Dutch Registry	<a href="https://www.onderzoekmetmensen.nl/en/">https://www.onderzoekmetmensen.nl/en/</a>	April 1, 2025
EU Clinical Trials	<a href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</a>	April 1, 2025
DRKS	<a href="https://drks.de/search/en/results">https://drks.de/search/en/results</a>	April 1, 2025
Iranian Registry	<a href="https://irct.behdasht.gov.ir/">https://irct.behdasht.gov.ir/</a>	April 1, 2025
ISRCTN	<a href="https://www.isrctn.com">https://www.isrctn.com</a>	April 1, 2025
Japan Registry	<a href="https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi">https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi</a>	April 1, 2025
South Korea CRIS	<a href="https://cris.nih.go.kr/cris/index/index.do">https://cris.nih.go.kr/cris/index/index.do</a>	April 8, 2025
Pan African Registry	<a href="https://pactr.samrc.ac.za/Search_v2.aspx">https://pactr.samrc.ac.za/Search_v2.aspx</a>	April 8, 2025
Sri Lanka CTR	<a href="https://slctr.lk/trials">https://slctr.lk/trials</a>	April 8, 2025
Thai Registry	<a href="https://www.thaiclinicaltrials.org">https://www.thaiclinicaltrials.org</a>	April 8, 2025
REec	<a href="https://reec.aemps.es/reec/public/web.html">https://reec.aemps.es/reec/public/web.html</a>	April 9, 2025
CTRI	<a href="https://ctri.nic.in/Clinicaltrials/advancesearchmain.php">https://ctri.nic.in/Clinicaltrials/advancesearchmain.php</a>	April 9, 2025
PubMed	<a href="https://ftp.ncbi.nlm.nih.gov/">https://ftp.ncbi.nlm.nih.gov/</a>	April 9, 2025

After collection, the raw data was subjected to systematic cleaning procedures to ensure consistency and reliability across sources:

- **Intra-source de-duplication:** Duplicate entries within the same registry were detected and removed using unique identifiers (such as trial registration numbers), and corroborated using additional metadata like titles.
- **Inter-source de-duplication:** Clinical trials registered in multiple registries were identified via fuzzy matching on titles. Duplicate records across sources were merged into a single one.
- **Field normalization:** Metadata fields such as trial status, registration date, and condition labels were standardized across sources to ensure consistent querying.
- **Missing value handling:** Entries with missing or incomplete critical fields were flagged.

These operations minimized noise, reduced redundancy, and created a unified and clean dataset suitable for benchmarking tasks.

### A.2 Studies table

There are three main sources of clinical trial records in our dataset: ClinicalTrials.gov, global registries, and PubMed. ClinicalTrials.gov records are highly structured, and we extracted key attributes such as trial type, sponsor, start year, and phase from the AACT database <sup>1</sup>.

In contrast, trial data from global registries are more heterogeneous and often semi-structured. Taking the processing of ANZCTR records as an example, we manually curated and standardized each trial entry to align with our unified schema. First, we used the "Registration number" column as the unique identifier for each study and assigned it as the 'study\_id'. Trial results were extracted from the "Results – plain English summary" field and, when available, supplemented with citation links from "Citation/DOI/link/details." We also processed structured eligibility information: for instance, the gender field was standardized by mapping values like "Both males and females" to a normalized label "MALE/FEMALE," ensuring consistency across sources. Age eligibility was retained from the "Minimum age" and "Maximum age" fields, and healthy volunteer status was preserved from the corresponding binary field. Trial phases were parsed by checking substrings within the "Phase"

<sup>1</sup><https://aact.ctti-clinicaltrials.org/>

column and converting them into discrete labels such as ‘PHASE1’, ‘PHASE2’, etc. Additionally, we extracted outcome information from the “Primary outcome” and “Secondary outcome” fields and abstracted trial objectives from the “Brief summary” column. These extracted attributes were compiled into a standardized table that serves as the ANZCTR subset of the merged dataset.

Moreover, clinical trials from publications like PubMed are essentially unstructured, typically presented as free-text abstracts without standardized fields. To extract structured information, we developed a rule-based pipeline that leverages regular expressions to identify key attributes embedded in the abstract. For each paper, we first extract the PubMed ID as the unique ‘study\_id’ and retain the abstract and title as primary textual content. We then parse trial phases by searching for standard mentions such as “Phase I” or “Phase 3b” across both title and abstract, and map these to a normalized phase label (e.g., ‘PHASE1’, ‘PHASE2’, etc.). To approximate sample size, we detect phrases like “XX participants” or “XX patients” and extract the numerical value as the actual accrual count. Additionally, we identify trial results by aggregating sentences prefixed with sections such as “Results:” or “Conclusions:” when available in the abstract. This approach allows us to recover basic outcome information despite the absence of structured metadata. While this method does not capture the full complexity of trial protocols, it provides a scalable way to convert a large volume of unstructured publications into structured records suitable for downstream analysis.

### A.3 Conditions table

To standardize disease conditions associated with each trial, we extracted Medical Subject Headings (MeSH) terms using the NCBO BioPortal Annotator API<sup>2</sup>. This process was applied only to non-ClinicalTrials.gov sources (e.g., PubMed, Embase, and international registries), as ClinicalTrials.gov conditions are already standardized. We used the official title and brief summary of each trial as input to retrieve disease-related MeSH terms (semantic type T047) and their hierarchical ancestors. The resulting MeSH types were labeled as mesh-list (primary condition), mesh-ancestor (intermediate ancestors), and mesh-ancestor-main (top-level ancestor).

### A.4 Drugs Table

To construct a comprehensive drugs table, we extract intervention mentions from three primary sources: (1) ClinicalTrials.gov and (2) PubMed. For ClinicalTrials.gov, we include entries where `intervention_type` is labeled as DRUG. For PubMed, we extract the intervention component (“I”) from PICO triplets and apply a lexicon-based filter to retain only drug-related mentions, excluding non-drug interventions such as procedures, devices, or behavioral treatments.

All extracted raw mentions are then processed through a multi-stage drug normalization and mapping pipeline (Figure 1). The pipeline begins with name normalization: (1) removing common treatment-related suffixes such as “therapy” or “tablet”, (2) cleaning noisy strings by removing typographic artifacts, and (3) handling special cases including abbreviations and regional variants.

Next, drug names undergo RxNorm resolution via a dual approach combining local and remote resources. (1) Local mapping attempts to match names against a pre-indexed RxNorm database with curated mappings. (2) If local matching fails, we query the official RxNorm API, parse the returned XML, and extract the corresponding RXCUI. (3) If both methods fail, we request spelling suggestions from the API and retry mapping using the suggested variants.

For drug names successfully mapped to RxNorm, we proceed to DrugBank resolution. (1) We first attempt to map the resolved RXCUI to a DrugBank ID via a curated RxNorm-to-DrugBank mapping table. (2) If that fails, or if RxNorm mapping was unsuccessful, we apply a direct DrugBank matching routine using exact string matching, synonym expansion, brand name resolution, and fuzzy matching based on character edit distance.

This process results in three possible outcomes: (1) drug names mapped to both RxNorm and DrugBank, (2) drug names mapped to DrugBank only, and (3) drug names that remain unmapped after all resolution steps.


Table 5 summarizes the drug mapping statistics for each data source, including total unique drug mentions, RxNorm mapping counts and rates, and DrugBank resolution results.

---

<sup>2</sup><https://bioportal.bioontology.org/annotator>

Supplementary Table 5: Drug mapping statistics across data sources.

Source	Total Drugs	RxNorm Mapped	RxNorm Rate (%)	DrugBank Mapped	DrugBank Rate (%)
PubMed	953,361	579,035	60.74	241,879	25.37
ClinicalTrials.gov	366,214	290,371	79.29	273,509	74.69



Supplementary Figure 1: Pipeline for drug name normalization and standardization. Drug names are cleaned, mapped to RxNorm, and subsequently resolved to DrugBank identifiers using a combination of indirect and direct strategies.

To further enrich the standardized drug table, we annotate each drug entry with regulatory approval status. Specifically, we compile lists of drugs approved by three major regulatory agencies: the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). These lists are sourced from DrugCentral 2023 [33]<sup>3</sup>, which provides a consolidated view of approval data across jurisdictions.

Approval annotations are applied by checking each drug's normalized name, RxNorm-mapped name, and DrugBank-mapped name against the cleaned lists of approved drug names. A drug is marked as approved by a given agency if any of these name variants match an entry in the corresponding list. This process enables us to systematically track the clinical regulatory status of drugs within our

<sup>3</sup><https://drugcentral.org/>

dataset, aiding downstream tasks that require distinguishing between approved and experimental interventions.

### A.5 Trial results table

To construct the Trial Result Table, a core component for the evidence summarization benchmark task, we systematically extracted key findings from two primary types of sources within our TRIAL-PANORAMA database: 1) published clinical trial literature, encompassing abstracts from PubMed, and 2) structured trial data directly from ClinicalTrials.gov registry entries. For all sources, the extraction process focused on identifying the core PICO (Population, Intervention, Comparator, Outcome) elements.

For published trial literature, a large language model (LLM), gpt-4o-mini, automatically extracted PICO components from PubMed abstracts. For data from ClinicalTrials.gov, a custom rule-based parser processed the structured JSON trial records, focusing on those with reported results (i.e., resultsSection present and outcome measures having a reportingStatus of 'POSTED'). The extracted trial results include:

- **P (Patient or problem):** Study population, conditions, and characteristics.
- **N (Number of subjects):** Total participants in the population group.
- **Outcomes (per arm):** For each reported outcome, the associated intervention arm (**I**), its status as a control (**C**, boolean flag), and detailed outcome results (**O**), including quantitative data and conclusions.

This process yielded a consistent, structured output for each abstract and document from ClinicalTrials.gov. Information extracted from both published literature and ClinicalTrials.gov was harmonized and consolidated into a unified Trial Result Table. Each row in this table represents a specific outcome from a particular trial arm. The prompt for LLM extraction is shown below.


```
""
Given the following clinical trial paper abstract, your task is to extract the key
trial information using the PICO framework. The PICO framework consists of the
following components:
Patient or problem (P): Who is the patient or what is the population or condition
being addressed? Report detailed information including the population size,
condition, and any relevant characteristics.
Intervention or control (I/C): What is the main intervention, treatment, or control
being considered? Report detailed information including the intervention,
including dosage and duration if applicable.
Outcome(s) (O): Extract detailed results and conclusions related to the outcomes,
including numbers, p-values, and outcome-related and statistical conclusions
if applicable.

Please return a list of reported outcome measures. Each reported outcome item
should include the intervention (I) or Control (C) used and the detailed
corresponding outcomes (O) of the intervention / control. Flag the control
group if applicable. Only extract the information that is explicitly mentioned
in the abstract. If any of the components are not mentioned in the abstract,
please indicate that they are not available.

Title: {title}
Abstract: {abstract}
""
```

### A.6 Trial outcomes table

To extract trial outcomes, we developed two distinct workflows for trials registered on ClinicalTrials.gov and those from other international sources. For ClinicalTrials.gov trials, we first categorized them based on overall status into: (1) completed, (2) terminated/withdrawn/suspended, and (3) other (e.g., recruiting, not active, withheld). We focused on completed and terminated trials to derive



Supplementary Figure 2: (a) Trial outcome extraction workflow. Completed trials are labeled using outcome measures and matched PubMed abstracts. Terminated trials are categorized by mapping stop reasons to predefined outcome types via keyword similarity. (b) Distribution of extracted outcome types on trials from ClinicalTrials.gov.

fine-grained outcome types using multiple sources, including publications and reported results, as shown in Supplementary Figure 2.

For completed trials, if explicitly labeled as *approved for marketing*, this outcome type was directly recorded. For the remaining trials, we identified matched publications by selecting the top two PubMed abstracts most relevant to the trial's official title using text similarity. We also extracted primary outcome measures from ClinicalTrials.gov. To determine whether a trial had a positive or negative outcome, we used *GPT-4o* to infer if the primary endpoint was met, based on the trial title, matched abstracts, and outcome measures. For trials without relevant abstracts or unclear outcomes, we used reported p-values for primary outcomes, applying two thresholds (0.01 and 0.05) to assign outcome types. The prompt for outcome type extraction as follows:

```

"""
TASK:
You are a clinical trial expert. You are given a clinical trial with NCT ID
[nct_id] and its official title: [official_title].

The primary outcomes of the trial are: [primary_outcomes].

```

```

Based on the related articles of the trial given below, please determine if the
trial is likely to have a positive or negative outcome.
A positive outcome means that the trial has achieved any of its primary endpoints
or outcomes. Negative outcome means that the trial has not achieved any of its
primary endpoints or outcomes.
If the outcome is unclear or unable to be inferred from the articles below, please
choose "unknown".

Articles:
1. Title: [top_1_similar_article_title]
Abstract: [top_1_similar_article_abstract]

1. Title: [top_2_similar_article_title]
Abstract: [top_2_similar_article_abstract]

OUTPUT:
Please provide a short answer by choosing one of the following options:
positive outcome
negative outcome
unknown

Do not provide any explanation or additional information.
"""

```

To derive fine-grained outcome types for terminated trials, we first embedded the stop reasons and visualized their clusters to identify representative keywords, which were grouped into predefined outcome types (Supplementary Figure 2). We further enriched these keywords using an LLM. For each trial, we computed similarity scores between the reported reason and the enriched keyword sets using a cross-encoder (ms-marco-MiniLM-L-12-v2), and assigned the outcome type with the highest average similarity. For trials from non-U.S. registries, we filtered those with reported results, which were in unstructured text format. We provided the trial title, primary outcome measures, and result text to *GPT-4o* to infer the trial outcome.

## A.7 Relations table

Supplementary Table 6: Statistics of the relation types in the relations table.

Relation Type	Count	Percentage (%)
PubMed - cite - PubMed	349,680	37.177
PubMed - exclude - PubMed	237,076	25.205
PubMed - include - PubMed	180,827	19.225
PubMed - linked_to - ClinicalTrials.gov	167,121	17.768
ClinicalTrials.gov - linked_to - JAPAN	2,787	0.296
PubMed - include - ClinicalTrials.gov	954	0.101
ClinicalTrials.gov - linked_to - KOREA	632	0.067
PubMed - cite - ClinicalTrials.gov	425	0.045
PubMed - exclude - ClinicalTrials.gov	406	0.043
ClinicalTrials.gov - linked_to - GERMAN	331	0.035
ClinicalTrials.gov - linked_to - ANZCTR	201	0.021
ClinicalTrials.gov - linked_to - PAN_AFRICAN	56	0.006
ClinicalTrials.gov - linked_to - SRI_LANKA	37	0.004
ClinicalTrials.gov - linked_to - CHICTR	31	0.003
ClinicalTrials.gov - linked_to - DUTCH	18	0.002

We implemented a multi-stage data processing pipeline centered on Cochrane Library reviews and their linked PubMed metadata to construct structured relationships between systematic reviews, clinical trials, and associated publications. Each review was first matched to its corresponding PubMed ID, and the full-text XML was parsed to extract structured reference sections. Using a custom reference extraction function, we identified citations grouped under section titles such as *references to studies included in this review*, *excluded from this review*, and *awaiting assessment*. For



each cited study, we extracted the PubMed ID and, when available, trial registry identifiers such as NCT numbers using regular expressions applied to the citation text. We formalized these relationships as triples in the format (head\_id, relation\_type, tail\_id), where head\_id is the PubMed ID of the review, tail\_id is the PubMed ID of the referenced study, and relation\_type is one of include, exclude, or cite, denoting the review’s assessment of the study.

We further enriched these relationships by linking PubMed studies to ClinicalTrials.gov trial records. This linkage was established through two mechanisms: first, by inspecting the AccessionNumber field in the PubMed XML to identify embedded NCT numbers; and second, by applying regular expressions to the abstract text to extract any mentioned NCT identifiers. In addition, we extended this mapping to include cross-registry linkages. For example, NCT numbers occasionally appear in records from other national trial registries; in such cases, we created edges of type link\_to to represent the equivalence between records referring to the same underlying trial across different sources. The statistics of all the relation types are in Supplementary Table 6.

## A.8 Dispositions table

Disposition reflects an essential aspect of a clinical trial: the design of experimental arms, including details such as the target treatment, administration schedule, duration, and dosage. To extract this information from ClinicalTrials.gov, we processed two complementary data sources: the trial design groups and their associated interventions. We began by loading and standardizing the relevant tab-separated files, namely design\_groups, interventions, and the linking table design\_group\_interventions. Key columns were normalized (e.g., renaming id to design\_group\_id or intervention\_id), and the data were merged using shared nct\_id and identifier fields. This enabled us to associate each design group with its corresponding intervention metadata. The resulting dataset provides, for each trial arm, a structured mapping that includes the intervention type (e.g., drug, device), group type (e.g., experimental, active comparator), treatment name, and descriptive text detailing the treatment protocol.


For publications, we extracted trial results in PICO format, where each unique pairing of the Population (P) and Intervention (I) elements is treated as a distinct disposition. From these pairs, we constructed corresponding trial arms that align with the disposition structure used in ClinicalTrials.gov. Each derived arm includes fields such as treatment name, description, and group type, allowing for consistent representation and integration across both registry-based and publication-based sources.

## A.9 Biomarkers table

Biomarkers, particularly therapeutic biomarkers (ThMARs), are critical to the design and execution of clinical trials. ThMARs have become essential in both clinical development and practice across therapeutic areas. Five major types of ThMARs have been identified, each playing a distinct role in drug discovery and development: (1) *Pharmacodynamic Biomarkers*, which ensure the pharmacological effect of a therapy; (2) *Safety Biomarkers*, used to assess the likelihood or severity of therapy-induced toxicity; (3) *Monitoring Biomarkers*, which guide ongoing clinical management by tracking patient status over time; (4) *Predictive Biomarkers*, which help tailor therapies to individuals most likely to benefit; and (5) *Surrogate Endpoints*, which serve as proxies to accelerate therapy approval.

We leveraged TheMarker [34] as a curated reference source for therapeutic biomarkers (ThMARs) relevant to clinical trials. Our processing pipeline to identify and normalize biomarker mentions consisted of two stages. In the first stage, we employed a GPT-4o-mini model to extract candidate text spans from clinical trial descriptions, such as titles, abstracts, and outcome sections, that may contain therapeutic biomarkers. The model was prompted to directly extract potentially relevant mentions verbatim from the source text. For example, given a trial abstract, the model might identify spans such as “HER2-positive breast cancer” or “PD-L1 expression level” as candidate biomarkers.

In the second stage, we implemented a deterministic pattern matching module to normalize these candidate spans by linking them to standardized biomarker entries from TheMarker. This was achieved through a two-step matching strategy. First, we attempted an exact string match between the extracted phrase and the entries in a pre-indexed lookup table. If an exact match was found, the matched biomarker ID and corresponding metadata were recorded, and the phrase was classified with the match type exact\_multi\_word. If no exact match was found, we then attempted an



Supplementary Figure 3: The distribution of the most frequent biomarkers under each of the five therapeutic biomarker classes.

order-invariant match by sorting the tokens in the candidate phrase and comparing them against a token-sorted index of biomarker terms. This allowed us to recover phrases with slight reordering of words, such as matching “receptor estrogen alpha” to “estrogen receptor alpha,” and was labeled as `exact_multi_word_order_invariant`.

Each successful match was associated with a structured biomarker representation that includes: (1) `biomarker_name`, the canonical name of the matched biomarker; (2) `biomarker_class`, describing the functional or molecular category of the biomarker (e.g., protein, receptor); (3) `biomarker_type`, which corresponds to one of the five therapeutic biomarker types defined by TheMarker: *Pharmacodynamic*, *Safety*, *Monitoring*, *Predictive*, or *Surrogate Endpoint*; and (4) `biomarker_genes`, listing any specific genes associated with the biomarker when applicable. This structured mapping enables precise linkage between clinical trials and biomarker knowledge, facilitating downstream analyses on biomarker-driven trial design and therapeutic targeting.

Supplementary Figure 3 shows the distribution of the most frequent biomarkers under each of the five therapeutic biomarker classes. In the Predictive (PRD) category, *C reactive protein* and *Tumor necrosis factor* appear most frequently, reflecting their widespread use in identifying responsive patient subpopulations. The Surrogate (SUR) category is heavily dominated by *Blood pressure*, with over 60,000 mentions, followed by metrics such as *Bone mineral density* and *Serum creatinine*, commonly used as clinical endpoints in chronic disease trials. In the Pharmacodynamic (PDY) class, *Low density lipoprotein* and *Angiotensin converting enzyme* are among the most prominent, reflecting their roles in evaluating pharmacological activity, particularly in cardiovascular studies. For the Safety (SAF) biomarkers, *Granulocyte macrophage colony-stimulating factor* and *Hyaluronic acid* are the most frequently referenced, indicating their importance in monitoring adverse or toxic effects. Lastly, in the Monitoring (MOI) category, *Epidermal growth factor*, *HBV DNA*, and *CEA (Carcinoembryonic antigen)* are among the top markers used for longitudinal assessment of disease progression or therapeutic response. Overall, this distribution highlights the heterogeneity in biomarker utility across different therapeutic contexts, with some biomarkers, such as *C reactive protein* and *Blood pressure*, being widely applicable across multiple trial types.

## A.10 Endpoints table

Core Outcome Measurement Sets [35, 36] provide a standardized taxonomy for classifying clinical trial outcomes, comprising five high-level domains and their associated subdomains. We adopted this COMET taxonomy to categorize outcome measurements reported in clinical trials. To automate the classification process, we employed an in-context learning approach using a GPT-4o-mini model. For each trial, the model was prompted with structured instructions to first extract the *primary outcome measurement* from the trial abstract or description, and then assign it to the appropriate COMET domain and subdomain. The full prompt used in this process is shown below.

```
"""
You are a clinical research expert. Given a clinical trial abstract or description,
extract the PRIMARY OUTCOME MEASUREMENT (usually only one or at most three),
and classify them using the COMET taxonomy.

Follow these steps:
1. Extract the PRIMARY OUTCOME MEASUREMENT from the input text.
2. Classify the PRIMARY OUTCOME MEASUREMENT using the COMET taxonomy below.

COMET Taxonomy:

1. Mortality/survival
  - No subdomains

2. Physiological/clinical
  - Blood and lymphatic system outcomes
  - Cardiovascular outcomes
  - Endocrine outcomes
  - Gastrointestinal outcomes
  - General outcomes
  - Immune system outcomes
  - Infections and infestations outcomes
  - Metabolic and nutritional outcomes
  - Musculoskeletal and connective tissue outcomes
  - Neoplasms and related outcomes
  - Nervous system outcomes
  - Pregnancy and childbirth outcomes
  - Renal and urinary outcomes
  - Reproductive system and breast outcomes
  - Respiratory outcomes
  - Skin and subcutaneous tissue outcomes
  - Surgical and medical procedures outcomes
  - Vascular outcomes

3. Life impact
  - Delivery of care
  - Global quality of life
  - Perceived health status
  - Personal circumstances
  - Physical functioning
  - Role functioning
  - Social functioning
  - Emotional functioning/wellbeing
  - Cognitive functioning
  - Sleep
  - Fatigue

4. Resource use
  - Hospital
  - Need for further intervention
  - Societal/carer burden
  - Other resource use

5. Adverse events/effects
```

```

- Any subdomain

Return your output as a list of JSON objects, one per outcome, in the following
format:

[
  {{
    "outcome": "<brieft name of the primary outcome measurement>",
    "domain": "<COMET domain>",
    "subdomain": "<COMET subdomain or null>"
  }},
  ...
]

Input text:
{outcome_text}
"""

```

The prompt included the full taxonomy definitions as context, covering domains such as *Mortality/Survival*, *Physiological/Clinical*, *Life Impact*, *Resource Use*, and *Adverse Events*, along with their respective subdomains. The model output was formatted as a list of JSON objects, each containing the outcome name, its mapped domain, and subdomain. This approach allowed for flexible, semantically aware interpretation of unstructured outcome descriptions, reducing the need for hand-crafted rules while achieving fine-grained alignment with the COMET classification. The result is a structured, interpretable dataset of standardized clinical trial endpoints that facilitates cross-trial comparisons, systematic reviews, and meta-analyses.

## A.11 Adverse events table

The Adverse Event Table is systematically populated by processing the `adverseEventsModule` found within the `resultsSection` of structured JSON records from ClinicalTrials.gov. The primary aim of this table is to provide a comprehensive overview of the safety profiles reported in these clinical trials.

Adverse event information was extracted from ClinicalTrials.gov data using a custom rule-based parser. We process the JSON records to identify and structure reported adverse events. The key information extracted includes:

- **Trial Arm Identification (I/C):** Distinct trial arms (or "event groups") are identified from the `eventGroups` list. The title and description of each group are combined to form a descriptive string for the intervention or comparator arm.
- **Adverse Event Details:** For each arm, both "serious" (`seriousEvents`) and "other" (`otherEvents`) adverse event categories are processed. For each reported event, the parser extracts:
  - The specific term used to describe the event (e.g., "Nausea").
  - The `organSystem` affected.
  - The frequency of the event within that specific arm, detailed as `numAffected` (number of participants experiencing the event) and `numAtRisk` (total participants in that arm). An event is only recorded for an arm if `numAffected` is greater than zero.
- **Structured Data per Event Instance:** For each adverse event occurring in a specific trial arm, the following structured information is captured:
  - The adverse event Term.
  - A comprehensive Description string that includes the `organSystem`, any associated notes, and the specific frequency of the event in that arm (formatted as "Frequency: X affected / Y at risk").
  - An `is_serious` boolean flag to indicate if the event was classified as serious by the trial reporters.

The extracted and structured adverse event data is then assembled into a flattened tabular format. Each row in the final Adverse Event Table represents a single adverse event term as it was reported for a specific trial arm.

To enhance standardization and facilitate analysis, the reported adverse event Terms are mapped to the Medical Dictionary for Regulatory Activities (MedDRA). This mapping utilizes the MedDRA hierarchy files (LLT, PT, HLT, HLTG). The corresponding MedDRA code is then added to the table.

This systematically constructed Adverse Event Table, linked by NCTID and trial arm descriptions, serves as a valuable resource for safety analyses and complements the efficacy-focused Trial Result Table within the TRIALPANORAMA database.

## B Benchmark building: Systematic review tasks

### B.1 Study search

Supplementary Table 7: Example instance of Study Search

Source PubMed ID: 38078494
<p><b>Question:</b> Generate search query to find PubMed studies based on the systematic review setup as below.</p> <ul style="list-style-type: none"> <li>• <b>Background:</b> Epilepsy is a common neurological disorder, affecting 0.5% to 1% of the population. In nearly 30% of cases, epilepsy is resistant to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is a second-generation antiseizure medication. When used as an add-on (in combination with other antiseizure medications), lamotrigine can reduce seizures, but with some adverse effects.",</li> <li>• <b>Objectives:</b> "To evaluate the benefits and harms of add-on lamotrigine, compared with add-on placebo or no add-on treatment in people with drug-resistant focal epilepsy.",</li> <li>• <b>Selection criteria:</b> We included randomised controlled trials (RCTs) that investigated add-on lamotrigine versus add-on placebo or no add-on treatment in people of any age with drug-resistant focal epilepsy. We used data from the first period of eligible cross-over trials.</li> </ul> <p><b>Ground-truth studies (PubMed ID)</b> "20696552", "2612495", "8937535", "10563619", "2498073", "2127016", "8232944", "8112232", "17938371", "18077797", "8505632", "8453943"</p>

**Definition & Motivation.** This task simulates the study search step in conducting systematic reviews, where the model must comprehend a given research question and synthesize a corresponding search query to retrieve relevant studies for inclusion. The key motivation behind this task is to streamline a traditionally labor-intensive process that typically requires the expertise of trained librarians, particularly due to the complexity and variability of search query formats across literature databases. Automating this step can significantly accelerate systematic review workflows. An example instance is presented in Supplementary Table 7.

**Input & Output.** The input for this task includes the setup of a systematic review, consisting of the research background, objective, and study selection criteria. The model is expected to generate a structured search query, which is then submitted to the PubMed Search API to retrieve the top 500 results and their associated PubMed IDs. A successful output should go beyond simple keyword extraction, incorporating semantic understanding and augmentation of the input to produce a comprehensive and effective query.

**Dataset Construction.** We constructed the dataset using a relation table that links systematic reviews to primary studies. Specifically, we focused on instances with the relation type `include`, indicating that the study was selected for inclusion in the review. For each review, we parsed its full text to extract relevant sections and used the linked PubMed abstracts as ground-truth targets. This process resulted in a dataset of 8,104 examples derived from systematic review articles, covering

more than 180,000 included PubMed studies. We reserved the most recent 100 reviews as a held-out test set.

**Evaluation Metrics.** We evaluate this task as a retrieval problem by measuring how many ground-truth studies appear in the top search results produced by the model-generated query. Specifically, we report Recall@100 and Recall@500, reflecting the number of included studies retrieved among the top 100 and 500 PubMed results, respectively.

Supplementary Table 8: Example instance of Study Screening

Source: PubMed ID: 38994714
<p><b>Background:</b> Cystic echinococcosis is a parasitic infection mainly impacting people living in low- and middle-income countries. Infection may lead to cyst development within organs, pain, non-specific symptoms or complications including abscesses and cyst rupture. Treatment can be difficult and varies by country. Treatments include oral medication, percutaneous techniques and surgery. One Cochrane review previously assessed the benefits and harms of percutaneous treatment compared with other treatments. However, evidence for oral medication, percutaneous techniques and surgery in specific cyst stages has not been systematically investigated and the optimal choice remains uncertain.</p> <p><b>Objective:</b> To assess the benefits and harms of medication, percutaneous and surgical interventions for treating uncomplicated hepatic cystic echinococcosis.</p> <p><b>Selection Criteria:</b> We included randomized controlled trials (RCTs) in people with a diagnosis of uncomplicated hepatic cystic echinococcosis of World Health Organization (WHO) cyst stage CE1, CE2, CE3a or CE3b comparing either oral medication (albendazole) to albendazole plus percutaneous interventions, or to surgery plus albendazole. Studies comparing praziquantel plus albendazole to albendazole alone prior to or following an invasive intervention (surgery or percutaneous treatment) were eligible for inclusion.</p> <p><b>Candidate Studies:</b></p> <ul style="list-style-type: none"> <li>• <b>PMID: 32382859</b> — Comparison of PAIR and catheterization techniques for CE1 and CE3a liver hydatid cysts.</li> <li>• <b>PMID: 35708380</b> — [Title and abstract truncated for brevity.]</li> <li>• <b>PMID: 16927868</b> — [Title and abstract truncated for brevity.]</li> <li>• <b>PMID: 24464258</b> — [Title and abstract truncated for brevity.]</li> <li>• ... — (additional candidate studies omitted for space)</li> </ul> <p><b>Screening Labels:</b></p> <ul style="list-style-type: none"> <li>• 32382859 — <b>Included</b></li> <li>• 35708380 — <b>Included</b></li> <li>• 16927868 — <b>Excluded</b></li> <li>• ...</li> </ul>

## B.2 Study screening

**Definition & Motivation.** This task simulates the study selection step in a systematic review pipeline, where the model must assess the eligibility of candidate studies for inclusion based on the review’s predefined criteria. Given a systematic review’s background, objective, and eligibility criteria, along with a set of candidate studies retrieved from PubMed (each with a title and structured abstract), the model determines whether each study should be included or excluded. This step is often labor-intensive and requires detailed reasoning across clinical nuances and protocol designs. An example instance is shown in Supplementary Table 8.



**Input & Output.** The input to this task consists of the systematic review protocol (comprising the review’s background, objective, and selection criteria) and a list of candidate studies, each represented by its title and structured abstract. The output is a binary label (`included` or `excluded`) for each candidate study, indicating whether it meets the review’s eligibility criteria. Accurate performance requires the model to match eligibility conditions against sometimes subtle or incomplete cues in the candidate study abstracts.

**Dataset Construction.** We construct the dataset using reviews that have explicit inclusion and exclusion annotations for candidate studies, available from the `relations` table in our clinical trial knowledge base. For each review, we extract its background, objective, and selection criteria from the abstract, and retrieve associated candidate studies along with their labels (`included` or `excluded`) based on the relation types `include` and `exclude`. To ensure a balanced and informative evaluation, we downsample the candidate pool for each review to include a random mix of included and excluded studies, preserving diversity while controlling for class imbalance. Each instance contains up to 10 candidate studies, each with a title and structured abstract, paired with a single review protocol.

**Evaluation Metrics.** We evaluate model performance using three metrics: accuracy, precision, and recall. Accuracy reflects the overall proportion of correctly classified studies. Precision measures the proportion of correctly identified `included` studies among all studies predicted as included, while recall measures the proportion of truly `included` studies that were correctly identified by the model. These metrics jointly assess both correctness and completeness of model screening decisions.

### B.3 Evidence summarization

**Definition & Motivation.** This task simulates the final synthesis step of a systematic review, in which the model must draw a conclusion from the included studies’ findings. Given a self-contained multiple-choice question based on a Cochrane review’s objectives, the model selects the answer option that aligns with the review’s main conclusion. An example instance is shown in Supplementary Table 9.

**Input & Output.** The input to the evidence summarization task consists of a self-contained multiple-choice question generated from a Cochrane review abstract (including its answer options A, B, C, ...) together with the titles and full structured abstracts of all studies included in that review (ranging from 1 to 20 PMIDs). The model’s output is a single label (A, B, C, ...) corresponding to the correct conclusion. Successfully performing this task requires the model to comprehend scientific text, aggregate evidence across multiple documents, and map study findings to the correct conclusion.

**Dataset Construction.** First, Cochrane review abstracts are processed by GPT-4o using a prompt that instructs the model to generate a self-contained multiple-choice question based on the review objectives, to produce answer options covering plausible outcomes, and to output only valid JSON with the keys `question`, `options`, and `answer`. The prompt also forbids referencing the original review by phrases such as “based on” to ensure questions are fully self-contained, and the model is run at temperature 0 to guarantee deterministic outputs. Next, for each generated question, we retrieve the included-study PMIDs from the review metadata and load the corresponding titles and structured abstracts from our PubMed cache, discarding any entries with zero or more than twenty included studies. Finally, the remaining  $N$  examples are sorted by numeric PMID (serving as a proxy for publication date); the most recent 1 000 examples form the *test* set, the preceding 500 form the *validation* set, and the remainder form the *training* set.

**Evaluation Metrics.** We report accuracy and macro-F1 to account for class imbalance across answer choices.

## C Benchmark building: Trial design tasks

### C.1 Arm design

**Definition & Motivation.** This task assesses whether the model can identify the correct treatment arms and intervention details for a given clinical trial. Based on the trial’s title and brief summary, the

Supplementary Table 9: Example instance of Evidence Summarization

Source PubMed ID: 10796093
<p><b>Question:</b> What were the findings regarding the effectiveness of bed rest in hospital for women with suspected impaired fetal growth compared to ambulatory management? Please answer this question based on the information provided below:</p> <p>{ title and abstract of included studies }</p> <p><b>Options:</b></p> <ul style="list-style-type: none"> <li>A. Bed rest in hospital significantly improved fetal growth parameters and neonatal outcomes.</li> <li>B. Bed rest in hospital significantly worsened fetal growth parameters and neonatal outcomes.</li> <li>C. There were no significant differences in fetal growth parameters and neonatal outcomes between bed rest in hospital and ambulatory management.</li> <li>D. Bed rest in hospital was found to be harmful to both the mother and the fetus.</li> </ul> <p><b>Answer:</b> C</p>

model must choose among four candidate descriptions the one that accurately represents the trial’s arm labels, arm types, and assigned interventions. An example instance is shown in Supplementary Table 10.

**Input & Output.** The model is provided the official trial title and summary, followed by four arm descriptions that list the group labels, intervention types, and associated treatments. It must return the label corresponding to the correct description.

**Dataset Construction.** We start with sets of up to four trial identifiers drawn from trials cited together in the same Cochrane review. For each identifier, a script extracts the arm groups and individual intervention details from our trial metadata. If fewer than four candidates are available, additional trials are added at random (with a fixed seed for reproducibility). To create challenging distractors, incorrect descriptions are drawn from the same arm and intervention information of other trials cited by that review. All items are then sorted by the numeric portion of the trial identifier and partitioned so that the latest 1,000 trials form the test set, the next 500 form validation, and the rest form training.

**Evaluation Metrics.** We report accuracy and macro-F1 to account for class imbalance across answer choices.

## C.2 Eligibility criteria design

**Definition & Motivation.** This task measures the model’s ability to match a trial’s inclusion and exclusion criteria. Given a trial’s title and summary, the model must select, from four text options, the one that accurately lists the trial’s eligibility rules. An example instance is shown in Supplementary Table 11.

**Input & Output.** The model receives the trial title and summary along with four candidate eligibility criterion sets. It must output the correct option label.

**Dataset Construction.** For eligibility criteria, dataset construction follows the same approach as in Arm Design: we form candidate sets from trials cited by the same Cochrane review, extract each trial’s eligibility rules from our metadata, pad with random trials when needed, and draw distractors from other cited trials to ensure relevance. Examples are then sorted by the numeric part of the trial identifier and split into test (latest 1,000), validation (next 500), and training (remainder).

Supplementary Table 10: Example instance of Trial Arm Selection

Source NCTID: NCT00000150

**Question:** Please select the arm or intervention descriptions that belong to the clinical trial below.

*Title:* Submacular Surgery Trials (SST)

*Brief Summary:* To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation. To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient’s perception of health- and vision-related “quality of life,” as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36), the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with AMD not suitable for laser treatment.

**Options:**

- A. Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
- B. Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab  
Arm Label: control; Type: NO\_INTERVENTION; Interventions: N/A  
Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab
- C. Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
- D. Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

**Answer:** C

**Evaluation Metrics.** We report Accuracy and macro-F1 to account for class imbalance across answer choices.

### C.3 Endpoint design

**Definition & Motivation.** This task evaluates whether the model can identify the primary outcome measures of a clinical trial. Based on the trial title and summary, the model must pick the option that lists the correct primary endpoints. An example instance is shown in Supplementary Table 12.

**Input & Output.** The input consists of the trial title and summary plus four outcome descriptions that concatenate the primary measures and any associated timeframes. The model must choose the correct label.

**Dataset Construction.** For primary endpoints, dataset construction also follows the Arm Design template: trials cited together provide candidate sets, we extract each trial’s primary outcomes from our metadata, pad with random examples if needed, and sample distractor options from other cited trials. The resulting items are ordered by the numeric portion of the trial identifier and divided into test (latest 1,000), validation (next 500), and training splits.

**Evaluation Metrics.** We report Accuracy and macro-F1 to account for class imbalance across answer choices.

Supplementary Table 11: Example instance of Trial Eligibility Criteria Selection

Source NCTID: NCT00004563

**Question:** Please select the eligibility criteria that correspond to the clinical trial below.

*Title:* Cyclophosphamide Versus Placebo in Scleroderma Lung Study

*Brief Summary:* To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.

**Options:**

- A. Inclusion: systemic scleroderma with active alveolitis on BAL fluid (neutrophilia  $\geq 3\%$  or eosinophilia  $\geq 2\%$ ) on CT; symptom onset (excluding Raynaud's) within 7 years; FVC 45–85% predicted; Mahler Dyspnea Index grade 2; Exclusion: DLCO  $< 30\%$  predicted; smoking in past 6 months; pulmonary abnormalities; pulmonary hypertension requiring therapy; prednisone  $> 10$  mg/day or prior cyclophosphamide  $> 4$  weeks or  $\geq 2$  IV doses; recent disease-modifying meds; ...
- B. Inclusion: idiopathic pulmonary fibrosis per ATS 2011, duration 6–48 months; age 40–80; %FVC  $\geq 50\%$   $\leq 90\%$ ; %DLCO  $\geq 30\%$   $\leq 90\%$ ; Exclusion: FEV1/FVC  $< 0.8$  post-bronchodilator; expected lung transplant within 1 year or on waiting list; known ILD cause; asthma/COPD history; active infection; ongoing IPF treatments; unstable cardiac/pulmonary disease in past 6 months; ...
- C. Inclusion: IPF diagnosis; age 40–80; FVC  $\geq 50\%$  predicted; DLCO  $\geq 35\%$  predicted; FVC or DLCO  $\leq 90\%$  predicted; no improvement in past year; walk 150 m in 6 min with sat  $\geq 83\%$  on  $\leq 6$  L/min O<sub>2</sub>; Exclusion: unable PFT; obstructive lung disease or airway hyper-responsiveness; expected lung transplant within 72 weeks; active infection; liver disease; cancer or other condition likely death within 2 years; diabetes; pregnancy/lactation; substance abuse; long QT syndrome; other IPF treatment; inability to take study medication; withdrawal from IPF trials; ...
- D. Inclusion: IPF diagnosis; age 40–80; FVC  $\geq 50\%$  predicted; DLCO  $\geq 35\%$  predicted; FVC or DLCO  $\leq 90\%$  predicted; no improvement in past year; walk 150 m in 6 min with sat  $\geq 83\%$  on  $\leq 6$  L/min O<sub>2</sub>; Exclusion: unable PFT; obstructive lung disease or airway hyper-responsiveness; expected lung transplant within 72 weeks; active infection; liver disease; cancer or other condition likely death within 2 years; diabetes; pregnancy/lactation; substance abuse; long QT syndrome; other IPF treatment; inability to take study medication; withdrawal from IPF trials; ...

**Answer:** A

#### C.4 Sample size estimation

**Definition & Motivation.** This task evaluates the model's quantitative reasoning by asking it to estimate the number of participants required for a clinical trial based on its design and stated statistical assumptions. Success requires understanding trial objectives, translating textual assumptions (effect size, significance level, power, dropout) into a numerical enrollment target, and applying standard sample-size formulas. An example instance is shown in Supplementary Table 13.

**Input & Output.** As input, the model receives: a narrative description of the trial design—official title, conditions, arm groups, interventions and primary outcomes, as well as a concise summary of the statistical assumptions extracted from the protocol text (treatment effect, alpha, power, expected dropout). The model must output a single integer corresponding to the estimated sample size.

**Dataset Construction & Splits.** We linked 5,737 PubMed protocols to their NCTIDs and identified 4,315 full-text sections titled “sample size” together with 5,678 CT.gov records containing enrollment counts. Matching the reported CT.gov enrollment with the corresponding paper section yielded 2 143 examples where the protocol paragraph explicitly mentions the official enrollment number. For each example, we used a deterministic prompt to summarize the paragraph into (1) effect-size assumptions,

Supplementary Table 12: Example instance of Trial Outcome Measure Selection

Source NCTID: NCT00000170

**Question:** Please select the outcome measures that correspond to the clinical trial below.  
*Title:* Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia  
*Brief Summary:* To determine whether success rate with atropine vs. patching therapy in <7 y olds with strabismic or anisometropic amblyopia is equivalent; To develop precise estimates of treatment success rates; To identify factors associated with successful treatment; To collect detailed amblyopia course data; Extended follow-up: Primary—long-term visual acuity at age 10 and 15; Secondary—compare long-term acuity at age 10 and 15 between patching+care vs. atropine+care.

**Options:**

- A. Visual acuity of amblyopic eye by HOTV (<7 y) or ETDRS ( $\geq 7$  y); measurement at 2 wk (strabismic/anisometropic/combined) and 4 wk (deprivation); ...
- B. Maximal improvement in visual acuity; ...
- C. Change in visual acuity from baseline to week 6 post-randomisation between arms; 6 wk; ...
- D. Visual acuity in amblyopic eye at 6 months; ...

**Answer:** D

(2) statistical parameters (significance level, power, dropout rate), and (3) the true enrollment. We then generated a question by combining trial metadata with these summarized assumptions. Finally, all examples were sorted by the numeric part of the NCTID; the most recent 1,000 form the test set, the next 500 the validation set, and the remainder the training set.

**Evaluation Metrics.** We report (1) the mean absolute error between predicted and actual enrollments, and (2) the proportion of trials for which the model’s estimate lies within  $\pm 20$  % of the true sample size.

### C.5 Trial completion assessment

**Definition & Motivation.** This task simulates a real-world feasibility analysis during clinical trial planning, where the model must assess whether a trial is likely to reach completion or be terminated early based on its protocol design. In addition, if a trial is predicted to terminate, the model is asked to identify the most likely reason for termination from a predefined set of categories (e.g., enrollment issues, safety concerns, lack of efficacy, operational problems). This reflects practical needs in the early design stage when sponsors assess trial viability. An example instance is shown in Supplementary Table 14.

**Input & Output.** Each example consists of structured metadata and protocol text for a registered interventional study, including trial phase, number of arms, masking, intervention model, primary purpose, arm descriptions, and detailed eligibility criteria. The output is a binary label indicating whether the trial was completed or terminated. For trials labeled as *terminated*, the model must also predict the most likely termination reason from one of several standardized categories.

**Dataset Construction.** We construct the dataset using completed and terminated interventional trials from ClinicalTrials.gov with known outcomes. Structured fields are extracted from the `studies`, `disposition`, `eligibility_criteria`, and `arms` tables in our trial database. Only trials with definitive outcome labels (i.e., *Completed* or *Terminated*) and non-missing eligibility criteria are retained. Termination reasons are normalized into broad categories using a curated taxonomy (e.g., enrollment issues, lack of efficacy, safety, sponsor decision). To avoid label leakage, we exclude any outcomes or termination reasons from the input text fields.

Supplementary Table 13: Sample Size Estimation Question

Source NCTID: NCT06330298

**Question:** Here is the design of a clinical trial:

Official Title: Improving Social Cognition and Social Behaviour in Various Brain Disorders.

Included conditions: Stroke; Multiple Sclerosis; Brain Tumor.

Study Arm groups: Experimental condition: Receives T-ScEmo Treatment (type EXPERIMENTAL; receives T-ScEmo between T0 and T1; interventionNames: ["Behavioral: Treatment social cognition and emotion regulation (T-ScEmo)"]); Waiting list group: Will be on waiting list instead of treatment (type NO INTERVENTION; duration T0–T1).

Interventions: Type BEHAVIORAL; name Treatment social cognition and emotion regulation (T-ScEmo); description T-ScEmo is a multifaceted protocol to improve social cognition, regulation of social behaviour and participation (Westerhof et al., 2017, 2019); 15×1 h live sessions + 5 online practice sessions; involves significant other and homework; armGroupLabels: [Experimental condition: Receives T-ScEmo Treatment]. Primary Outcomes: Change in social behaviour examined by proxy; difference T0→T2 on the Dysexecutive Questionnaire Social scales proxy version (DEX-Socproxy; Spikman et al., 2013; Westerhof-Evers, 2017); time frame: through completion (8–10 months).

Please estimate the sample size based on: significance level ( $\alpha = 0.05$ ), power ( $1 - \beta = 0.80$ ), and the group×time interaction in a repeated measures analysis.

**Answer:** 84

**Explanation:** The study of Westerhof-Evers et al. [9] found that the DEX-Socproxy had an effect size of Cohen's  $d = 0.2$  (Cohen's  $f = 0.10$ ) for the comparison between T0 and T2. From these data, a small to medium effect size of Cohen's  $f = 0.15$  was estimated for the current study. Therefore, the sample size is based on a power calculation for the main outcome measure (DEX-Socproxy) regarding the condition × time interaction (T0, T2) using repeated measures analysis with effect size Cohen's  $f = 0.15$ ,  $\alpha = 0.05$ , and power = 0.80 [29], resulting in a sample size of  $n = 62$ . However, to ensure balanced distribution across patient groups, a total sample size of  $n = 84$  will be used (42 patients per condition).

**Evaluation Metrics.** We evaluate trial completion prediction using accuracy. For terminated trials, termination reason classification is evaluated using macro-F1 to balance across categories with different frequencies.

Supplementary Table 14: Example instance of Trial Completion Assessment

Source NCTID: NCT02823470

**Study Title:** A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

**Study Design:**

- Allocation: Randomized
- Intervention Model: Parallel
- Masking: None
- Primary Purpose: Treatment
- Phase: Phase 4
- Number of Arms: 2

**Arms:**

- **Arm A** (Experimental): Activated smart device alerts and feedback  
*LUM/IVA: LUM 400 mg q12h / IVA 250 mg q12h through Week 48.*
- **Arm B** (Experimental): De-activated smart device alerts/feedback features  
*LUM/IVA: LUM 400 mg q12h / IVA 250 mg q12h through Week 48.*

**Inclusion Criteria:**

- CF diagnosis with F508del-CFTR homozygosity, FEV1  $\geq$  40% predicted, consented, willing to comply.
- ... [truncated for brevity]

**Exclusion Criteria:**

- Hepatic impairment, mechanical ventilation, pregnancy, recent investigational drug use, prior/current use of commercial LUM/IVA.
- ... [truncated for brevity]

**Outcome:** Terminated

**Reason for Termination:** Enrollment issues — study terminated early due to slow recruitment of patients.